Navigation Links
Children's Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
Date:9/10/2009

--Will Shorter Treatments Reduce Drug Resistance?--

PHILADELPHIA, Sept. 10 /PRNewswire-USNewswire/ -- In the largest study of its kind, pediatric researchers at The Children's Hospital of Philadelphia have received a federal contract for a project to determine the most beneficial method of using antibiotics to treat urinary tract infections (UTIs) in children.

The award, announced September 2 by the National Institute of Allergy and Infectious Diseases (NIAID), aims to answer key questions about the best use of antimicrobial drugs against UTIs, the most common disorder of the kidneys and urinary tract in early childhood. UTIs are highly treatable, but an infection that goes untreated may lead to serious kidney damage.

Because widespread antibiotic use has allowed bacteria to evolve strains that are resistant to common drugs, the new study will investigate whether using antibiotics over a shorter period than the standard 10 days is an effective treatment, while reducing the risk of drug resistance.

The initial award is for $1.5 million, with total funding of $13.8 million available over the project's six-year duration if clinical trial milestones are met. Theoklis Zaoutis, M.D., M.S.C.E., an infectious diseases specialist at the Center for Pediatric Clinical Effectiveness at The Children's Hospital of Philadelphia, is the principal investigator of the NIAID study. The clinical trial will enroll 700 children at two centers -- the Children's Hospital of Philadelphia and the Children's Hospital of Pittsburgh.

It will be the largest clinical trial to compare a short course versus the standard course of antimicrobial treatments for UTIs in children, said Zaoutis.

"Our goals will be to determine the optimal duration of antimicrobial treatment for UTIs," added Zaoutis. "This information will allow doctors t
'/>"/>

SOURCE The Children's Hospital of Philadelphia
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
2. Gilbert Hospital Continues Cutting Edge Treatments
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
6. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
7. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
8. Hospital to Hold MRSA Briefing for Media and Community Leaders
9. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
10. Providence Hospital Study Finds Communication System Leads to Faster Heart Attack Treatment
11. Allegheny General Hospital Performs First Liver Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
(Date:5/28/2015)... and HOUSTON , May 28, 2015 ... EPI) today reported financial results for the second quarter and ... specified otherwise, are expressed in Canadian dollars and in accordance ... Results ESSA recorded a net loss of ... ended March 31, 2015 (Q2-2015), compared to a net loss ...
(Date:5/28/2015)... , May 28, 2015  IRIDEX Corporation (NASDAQ: ... Financial Officer James H. Mackaness is scheduled to ... 2015, at 9:00 am PT in Los Angeles ... presentation may be accessed on the Event Calendar of the ... replay of the webcast will be available shortly after the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... the ASSERT Trial Presented at EULAR, BARCELONA, ... today at the European League Against Rheumatism ... patients with,ankylosing spondylitis (AS) who received REMICADE(R) ... spinal,mobility. In addition, REMICADE-treated patients showed sustained,reductions ...
... from 741-patient trial show those treated with,Prexige experienced ... , * Many patients with osteoarthritis also have ... can impact,cardiovascular risk[2],[3] , * Prexige approved in ... US for use in osteoarthritis patients , BASEL, ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 6
(Date:5/30/2015)... The results of a 40+ year study in ... to cause mesothelioma, regardless of the volume of exposure. ... Surviving Mesothelioma website. , The study conducted by ... found that, among the 138 cases of mesothelioma that ... of them happened at plants that had, at some ...
(Date:5/30/2015)... 2015 EHO offers a suite of ... gives hospices the ability to manage their drug-spend for ... business model, EHO has been able to compete with ... clients and survive among the giants of the industry. ... three years ago, it has simplified the way hospices ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Cyclist ... tour, “Wheels for the World 2015: Piles of ... to raise awareness about hemophilia and encourage individuals ... Life. , Save One Life supports nearly ... eleven developing countries through direct sponsorships, scholarships and ...
(Date:5/30/2015)... 30, 2015 This year the ... Pulmonary Horizons to offer one of the most diverse ... discuss successful practices to diagnose, treat and manage patients ... Pulmonary Horizons Conference is Interaction with Multidisciplinary Healthcare ... Overall Needs of Patients with COPD," said Brian W. ...
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with a new hanging ... signs ; making what was formerly an elite expensive ... points at a usual height of 16’-20’ are easily seen ... are very unique and more visible than the largest exhibits. ... labor and rigging the costs far outweigh the benefit of ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2
... a medical conference that takes place entirely online, announces participation of ... Prevention Center. Dr. Kaskel to present "Improved Patient Outcomes and ... ... MA (PRWEB) February 18, 2009 -- CardioCareLive , the first ...
... 18 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin ... company that controls,and operates pharmaceutical companies in ... that contractually controlled Beijing Liang Fang,Pharmaceutical Co., ... rights,transfer contract with Beijing Yipuan Bio-Medical Technology ...
... Has Resisted Well, - Continued Reduction in Net Debt, In millions of euros ... 168.4 ... 19.3 26.8, EBITDA margin ... Current operating income* 4.6 12.0, ...
... to educate, inform, and empower the people of Chicago, ... its 25-minute live call-in show, "Community Health," on Chicago ... 6:00 PM on Channel 21. Monday,s program, with ... the Balancing Center in Chicago will discuss the health ...
... Michael J. Fox Foundation for Parkinson,s Research awarded ... to develop neuroimaging technologies that would allow scientists ... protein in the living human brain. Such technologies ... and treatment of PD. Investigators could more accurately ...
... and survival is poorer, new report finds , , WEDNESDAY, ... rates continue to decline, an American Cancer Society report ... more advanced stages of cancer than whites, the report,s ... each stage of diagnosis of most types of cancers. ...
Cached Medicine News:Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 2Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 3Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 2Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 3Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 4Health News:PCAS: 2008 Results 2Health News:PCAS: 2008 Results 3Health News:Save Your Money and Your Health 2Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 2Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 3Health News:Cancer Death Rates Decline Among Blacks, But Disparities Linger 2Health News:Cancer Death Rates Decline Among Blacks, But Disparities Linger 3
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
... A revolutionary urological imaging ... benefits that translate into improved ... x 1k imaging technology physicians ... to see more anatomical detail ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
Medicine Products: